FDA Panel Backs Galleri Cancer Blood Test

A majority of an FDA advisory committee has recommended the Galleri multicancer early detection blood test, a decision reached with some apprehension. The molecular and clinical genetics panel voted 6-4 and 7-2, with one abstention, in favor of the test's potential utility. This endorsement represents a crucial milestone for GRAIL, the company that developed Galleri, as it seeks regulatory approval to make the test more widely available to the public. The Galleri test is designed to detect cancer signals from a blood sample, aiming to identify multiple cancer types in their early stages, often before symptoms manifest. Its proposed use is as an aid to screening in adults with a higher-than-average risk of developing cancer, based on age, medical history, or other factors. The committee's deliberations focused on the test's performance, including its ability to detect cancer signals and its accuracy in predicting the tissue of origin for a detected cancer. Concerns raised by committee members included the potential for false positive and false negative results, and the clinical utility of a positive result when the cancer signal is detected but the specific cancer type cannot be definitively identified. The test analyzes cell-free DNA (cfDNA) in the blood, looking for patterns that are characteristic of cancer. GRAIL has conducted extensive clinical trials, including the PATHFINDER study, which evaluated the test's performance in a real-world setting. The study results, presented to the committee, indicated that Galleri could detect cancer signals in a significant proportion of individuals diagnosed with cancer, and importantly, that it could predict the tissue of origin for many of these cancers. However, the committee also grappled with the implications of the test's sensitivity and specificity, particularly in the context of screening asymptomatic individuals. The recommendation from the advisory committee is non-binding, meaning the final decision on whether to approve Galleri for broader use will rest with the U.S. Food and Drug Administration (FDA) itself. The FDA will consider the committee's recommendation, along with all submitted data, when making its determination. Approval of Galleri could significantly alter cancer screening paradigms, potentially leading to earlier diagnoses and improved patient outcomes. However, the path to widespread adoption will likely involve further research, education for healthcare providers and patients, and careful consideration of the test's limitations and appropriate use.